Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.62 |
| ▸ | CA9 | Q16790 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | CA12 | O43570 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | CA1 | P00915 | 5/20 | 0.61 |
| ▸ | CA7 | P43166 | 1/20 | 0.61 |
| ▸ | MMP2 | P08253 | 4/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | MMP1 | P03956 | 3/20 | 0.57 |
| ▸ | MMP9 | P14780 | 3/20 | 0.57 |
| ▸ | MMP13 | P45452 | 3/20 | 0.57 |
| ▸ | MMP8 | P22894 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | MMP3 | P08254 | 2/20 | 0.56 |
| ▸ | MMP7 | P09237 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL29019330 | 0.96 | ALDH1A1 (0.59) | CA2CA9ALDH1A1CA12TSHR | |
| SCHEMBL25650178 | 0.87 | GAA (0.65) | CA2CA9ALDH1A1CA12TSHR | |
| SCHEMBL3415855 | 0.83 | GBA1 (0.61) | CA2CA9ALDH1A1CA12TSHR | |
| SCHEMBL6130629 | 0.83 | MMP2 (0.61) | CA2CA9ALDH1A1CA12TSHR | |
| SCHEMBL10289397 | 0.83 | CA2 (0.62) | CA2CA9ALDH1A1CA12TSHR | |
| SCHEMBL29259803 | 0.82 | CNR1 (0.60) | CA2CA9ALDH1A1CA12TSHR | |
| SCHEMBL16734878 | 0.81 | CA2 (0.56) | CA2CA9ALDH1A1CA12TSHR | |
| SCHEMBL3747089 | 0.81 | ADAMTS4 (0.58) | CA2CA9ALDH1A1CA12CA1 | |
| SCHEMBL6804107 | 0.81 | CA1 (0.58) | CA2ALDH1A1TSHRCA1MMP2 | |
| SCHEMBL5453607 | 0.81 | ALDH1A1 (0.58) | CA2CA9ALDH1A1CA12TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5437690-A | Using an n-alkyl aromatic sulfonamide as dye promoter in dyeing aromatic polyamides, polybenzimidazoles, polyimides | SPRINGS INDUSTRIES, INC. (US) | 1995-08-01 | — | — | US | claimed |
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230339997-A1 | CLASS OF PLATINUM COMPOUNDS FOR TREATING CANCER, AND METHOD FOR PREPARATION THEREOF | SHANGHAI HAIJU BIOLOGICAL TECHNOLOGY CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230076803-A1 | COMPOUND AND DRUG CONJUGATE, AND PREPARATION METHOD AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2023-03-09 | — | — | US | disclosed |
| US-11535643-B2 | Macrolides with modified desosamine sugars and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-12-27 | — | — | US | disclosed |
| EP-4053110-A1 | MODIFIER OF FOUR-MEMBERED RING DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2022-09-07 | — | — | EP | disclosed |
| US-5565570-A | REACTING AMINE WITH SULFONYL HALIDE IN INERT SOLVENT IN PRESENCE OF BASE TO FORM METAL SALT OF SULFONAMIDE, ACYLATING WITH ACTIVATED PHENANTHRIDINE-6-CARBOXYLIC ACID TO FORM CHEMILUMINESCENT SALT | ABBOTT LABORATORIES (US) | 1996-10-15 | — | — | US | disclosed |
| US-5545739-A | E.G., 5-METHYL-6-(N-2-CARBOXYETHYL-N=(2-CARBOXYETHYL)-PHENANTHRIDIN IUMCARBOXAMIDE CHLORIDE; IMMUNOASSAYS; STABILITY; SENSITIVITY | ABBOTT LABORATORIES (US) | 1996-08-13 | — | — | US | disclosed |
| US-5543524-A | FORMING A SULFONAMIDE FROM AND AMINE AND A SULFONYL HALIDE AND AND ACYLATING WITH A CARBONYL HALIDE OF AN ACTIVATED ACRIDINE SALT | ABBOTT LABORATORIES (US) | 1996-08-06 | — | — | US | disclosed |
| US-5468646-A | Chemiluminescent acridinium salts | ABBOTT LABORATORIES (US) | 1995-11-21 | — | — | US | disclosed |
| US-5437690-A | Using an n-alkyl aromatic sulfonamide as dye promoter in dyeing aromatic polyamides, polybenzimidazoles, polyimides | SPRINGS INDUSTRIES, INC. (US) | 1995-08-01 | — | — | US | disclosed |
| EP-0475707-B1 | Hot-melt ink composition | SEIKO EPSON CORP (JP) | 1995-03-22 | — | — | EP | disclosed |
| EP-0273115-B1 | Chemiluminescent acridinium and phenanthridinium salts | ABBOTT LAB (US) | 1994-09-07 | — | — | EP | disclosed |
| US-5230731-A | (Di)alkylbenzenesulfonamide | SEIKO EPSON CORPORATION (JP) | 1993-07-27 | — | — | US | disclosed |
| EP-0475707-A2 | Hot-melt ink composition | SEIKO EPSON CORPORATION (JP) | 1992-03-18 | — | — | EP | disclosed |
| US-4413013-A | N-(((ARYLFORMAMIDOYL)METHYLAMINO)THIO)-N-SUBSTITUTED SULFONAMIDES | THE UPJOHN COMPANY (US) | 1983-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | CA2 4417/4885CA9 4030/4885ALDH1A1 3319/4885 |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | ASGR1, LDLR, FCGR2A | CA2 4006/4885CA9 2593/4885ALDH1A1 3256/4885 |
| US-11535643-B2 | Macrolides with modified desosamine sugars and uses thereof | FUT6, MGAM, B3GNT2 | CA2 4530/4885CA9 1721/4885ALDH1A1 3204/4885 |
| US-20230076803-A1 | COMPOUND AND DRUG CONJUGATE, AND PREPARATION METHOD AND USE THEREOF | ABCG2, ABCB1, SLC10A1 | CA2 3840/4885CA9 152/4885ALDH1A1 278/4885 |
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | M6PR, ASGR1, IGF2R | CA2 4288/4885CA9 4129/4885ALDH1A1 4019/4885 |
| US-20230339997-A1 | CLASS OF PLATINUM COMPOUNDS FOR TREATING CANCER, AND METHOD FOR PREPARATION THEREOF | TP53, ERCC4, SLC19A1 | CA2 974/4885CA9 122/4885ALDH1A1 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.